Women's Libido stack

A female-focused research pairing built around the stronger clinical evidence for PT-141 and the more preliminary social-bonding rationale for oxytocin. PT-141 (bremelanotide) has the clearest women-specific evidence in this stack. Two randomized Phase 3 trials involving 1,267 premenopausal women with acquired, generalized HSDD found statistically significant improvements in sexual desire and reductions in associated distress compared with placebo. The FDA approval of the branded medicine Vyleesi is limited to this defined female population and does not apply to VCP research products. Oxytocin is involved in bonding and social-affiliative signalling, but that biology should not be confused with demonstrated treatment efficacy. Small randomized studies of oxytocin for female sexual function have produced mixed or null results, so any added intimacy or connection benefit remains uncertain. No human trial has tested PT-141 and oxytocin together. The combination is a research rationale rather than a clinically proven stack. Available Small (1 vial of each) or Large (2 vials of each), as vials, pen cartridges (+30%) or a nasal spray (+30%; 5mL Small, 10mL Large).